the drug-containing polymer into a disc with a substantially well-defined surface area and thickness. The adhesive polymer is spread along the circumference to form a strip of adhesive around the disc.

In a microreservoir system, the reservoir of the active substance is formed by first suspending the drug solids in an aqueous solution of water-soluble polymer, and then dispersing the drug suspension in a lipophilic polymer to form a plurality of microscopic spheres of drug reservoirs.

Other Embodiments

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

Other embodiments are within the claims.

What is claimed is:

1. A method of treating or reducing pain in a mammal in need thereof, said method comprising administering to said mammal a composition comprising a compound having the formula:

(I)



or

(II)



wherein

R^1 is H, C_{1-6} alkyl, halo, NO_2, CN, CO_2R^4, $CONR^4R^5$, SO_2R^4, $SO_2NR^4R^5$, OR^4, or NR^4R^5, wherein each of R^4 and R^5 is, independently, H, C_{1-6} alkyl, C_{6-12} aryl, heteroaryl, C_{1-4} alkaryl, or C_{1-4} alkheteroaryl,

R^2 is H, C_{1-6} alkyl, C_{6-12} aryl, heteroaryl, C_{1-4} alkaryl, or C_{1-4} alkheteroaryl, and

R^3 is H, C_{1-6} alkyl, C_{6-12} aryl, heteroaryl, C_{1-4} alkaryl, C_{1-4} alkheteroaryl, CO_2R^6, $CONR^7R^8$, SO_2R^6, or $SO_2NR^7R^8$, wherein R^6 is C_{1-6} alkyl, C_{6-12} aryl, heteroaryl, C_{1-4} alkaryl, or C_{1-4} alkheteroaryl and each of R^7 and R^8 is, independently, H, C_{1-6} alkyl, C_{6-12} aryl, heteroaryl, C_{1-4} alkaryl, or C_{1-4} alkheteroaryl; or

R^3 is as above and R^1 and R^2 together are represented by



-continued



wherein

the N, O, or S of the R^1/R^2 linkage forms a bond to the pyrimidinone ring and each of R^9, R^{10}, R^{11}, R^{12}, and R^{13} is, independently, H, C_{1-6} alkyl, C_{6-12} aryl, heteroaryl, C_{1-4} alkaryl, or C_{1-4} alkheteroaryl; or

R^3 is as above and R^1 and R^2 together are represented by



wherein

the N of the R^1/R^2 linkage forms a bond to the pyrimidinone ring, each of R^{12} and R^{13} is as above, and R^{14} is H, SH, OR^4, halo, NO_2, CN, CO_2R^7, $CONR^7R^8$, SO_2R^7, $SO_2NR^7R^8$,



C_{1-6} alkyl, C_{6-12} aryl, heteroaryl, C_{1-4} alkaryl, or C_{1-4} alkheteroaryl, wherein each of R^4, R^7 and R^8 is, independently, H, C_1-C_6 alkyl, C_6-C_{12} aryl, C_1-C_4 alkaryl, heteroaryl, or C_1-C_4 alkheteroaryl; or

R^1 and R^2 together are represented by



wherein

the N of the R^1/R^2 linkage forms a bond to the pyrimidinone ring, each of R^9, R^{10}, R^{11}, and R^{14} are as above, R^3 does not exist, and a double bond is formed between the carbon bearing R^{14} and the nitrogen bearing R^2,

in an amount sufficient to result in a reduction of BH4 biological activity and thereby treat or reduce pain.

2. The method of claim **1**, wherein said mammal is a human.

3. The method of claim **1**, wherein the pain is reduced by reducing the BH4 levels in primary sensory neurons or dorsal horn neurons.

4. The method of claim **3**, wherein said primary sensory neurons are in a dorsal root ganglion or a trigeminal ganglion.

5. The method of claim **4**, wherein said dorsal horn neurons are in the spinal cord or spinal nucleus of the trigeminal in the brainstem.